Deryusheva I V, Tsyganov M, Garbukov E Y, Ibragimova M K, Kzhyshkovska Ju G, Slonimskaya E, Cherdyntseva N V, Litviakov N V
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk 634050, Russia.
Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University; German Red Cross Blood Service Baden-Württemberg - Hessen; Mannheim, Germany.
Exp Oncol. 2017 Jul;39(2):145-150.
One of the factors providing the diversity and heterogeneity of malignant tumors, particularly breast cancer, are genetic variations, due to gene polymorphism, and, especially, the phenomenon of loss of heterozygosity (LOH). It has been shown that LOH in some genes could be a good prognostic marker.
To perform genome-wide study on LOH in association with metastasis-free survival in breast cancer.
The study involved 68 patients with breast cancer. LOH status was detected by microarray analysis, using a high density DNA-chip CytoScanTM HD Array (Affymetrix, USA). The Chromosome Analysis Suite 3.1 (Affymetrix, USA) software was used for result processing.
13,815 genes were examined, in order to detect LOH. The frequency of LOH varied from 0% to 63%. The association analysis identified four genes: EDA2R, PGK1, TAF9B and CYSLTR1 that demonstrated the presence of LOH associated with metastasis-free survival (log-rank test, p < 0.03).
The presence of LOH in EDA2R, TAF9B, and CYSLTR1 genes is associated with metastasis-free survival in breast cancer patients, indicating their potential value as prognostic markers.
导致恶性肿瘤，尤其是乳腺癌具有多样性和异质性的因素之一是基因变异，这是由基因多态性引起的，特别是杂合性缺失（LOH）现象。研究表明，某些基因中的LOH可能是一个良好的预后标志物。
对乳腺癌中与无转移生存期相关的LOH进行全基因组研究。
该研究纳入了68例乳腺癌患者。使用高密度DNA芯片CytoScanTM HD Array（美国Affymetrix公司）通过微阵列分析检测LOH状态。结果处理使用Chromosome Analysis Suite 3.1（美国Affymetrix公司）软件。
为检测LOH，共检测了13815个基因。LOH频率从0%到63%不等。关联分析确定了四个基因：EDA2R、PGK1、TAF9B和CYSLTR1，这些基因显示存在与无转移生存期相关的LOH（对数秩检验，p<0.03）。
EDA2R、TAF9B和CYSLTR1基因中存在LOH与乳腺癌患者的无转移生存期相关，表明它们作为预后标志物的潜在价值。
